Anti-Atezolizumab Polyclonal Antibody (AV974034)

데이터시트 제품 공유 정보 복사

가격(USD): $

사양:

50ug
100ug

수량:

문의하기

개요
이미지
참고 문헌
데이터시트

개요

카탈로그 번호

AV974034

설명

Anti-Atezolizumab Polyclonal Antibody (AV974034) is a rabbit polyclonal antibody detecting Atezolizumab in ELISA.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.

응용 분야

ELISA

숙주 종

Rabbit

이소타입

IgG

클론성

Polyclonal

면역원

Atezolizumab

타겟

Rabbit polyclonal to Tecentriq.

특이성

The product is specific for Atezolizumab. This antibody serves as an excellent positive control for Atezolizumab immunogenicity (ADA) assays.

내독소 수준

Please contact with the lab for this information.

정제

Purified by antigen affinity column.

등록번호

CAS: 1380723-44-3

RRID

Anti-Atezolizumab Polyclonal Antibody (abinScience Cat# AV974034, RRID:AB_3730354)

형태

Liquid

저장 완충액

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.

제품 사용 정보

응용 분야	희석
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

안정성 및 저장

The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.

배경

Atezolizumab with trade name Tecentriq, is an FDA-approved drug, which is a humanized programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma or metastatic non-small cell lung cancer.

참고사항

For research use only.

이미지

참고 문헌

데이터시트

Anti-Atezolizumab Polyclonal Antibody.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

재조합 단백질

항체

어세이 키트

Anti-Atezolizumab Polyclonal Antibody (AV974034)

개요

이미지

참고 문헌

데이터시트

빠른 접근

문의하기